United States: Eli Lilly shared encouraging trial results for its oral drug orforglipron, which led to a 16% rise in the company’s stock value after 1 p.m. ET on April 17. The once-daily medication adds to Lilly’s growing lineup, which includes well-known drugs like Mounjaro and Zepbound, according to USA Today.
What the Pill Targets
Orforglipron aims to lower blood sugar and support weight loss, offering new hope for managing type 2 diabetes and obesity—conditions projected to affect 760 million people worldwide by 2050.
Clinical Results Show Significant Progress
According to Lilly:
- A1C levels dropped between 1.3% and 1.6%, with many participants reaching levels below 6.5%, surpassing ADA targets.
- Those on the highest dose lost an average of 16 pounds, with no plateau observed during the study period.
Side Effects Within Expected Range
Some side effects were reported, mostly mild to moderate gastrointestinal issues, including:
- Diarrhea (up to 26%)
- Nausea (up to 18%)
- Constipation and vomiting (up to 17% and 14%)
However, analysts noted that the pill’s overall tolerability remained solid, with no significant liver concerns reported.
Convenient Use and Flexible Dosing
Participants could take the pill at any time of day without food restrictions, offering added convenience over injectable alternatives, according to USA Today.
What’s Next for Orforglipron?
Lilly stated that additional clinical trials and FDA approval are still required. This trial is one of seven planned Phase 3 studies to evaluate the drug’s safety and effectiveness for people living with diabetes and obesity.